We're at the @BAUNnurses Annual Conference in Manchester from 18-20 October. Visit us at Booth #36 to find out more about our Combat BRS #HIVEC® hyperthermic chemo delivery system with mitomycin C for NMIBC, plus the latest news on our phase 3 @HIVEC_HEAT trial.
#CombatCancer
Inspired by cancer-detecting sniffer dogs, electronic nose technology could be used to diagnose bladder cancer. A study of 335 participants achieved 87.5% accuracy, 81.8% sensitivity and 95.1% specificity using urine samples.
👉bit.ly/4eoM6Dw
#HIVEC #CombatCancer
Researchers at @MIT and @JohnsHopkins have developed a handheld microfluidic device that collects living cells from specific areas of the fallopian tube, potentially enabling earlier diagnosis.
👉bit.ly/4xTsxtZ
#HIPEC #CombatCancer
💥 @HIVEC_HEAT trial update – 3 new sites have opened! The phase 3 trial is evaluating the efficacy and safety of the Combat BRS (bladder recirculating system) HIVEC® treatment with mitomycin C for NMIBC as a bladder-sparing alternative in BCG-unresponsive patients.
#CombatCancer
Meet us at Booth E19 at the German Urological Congress in Düsseldorf today and tomorrow to find out more about our Combat BRS HIVEC® treatment for BCG-unresponsive NMIBC – including updates on our phase 3 @HIVEC_HEAT trial.
@DGUrologie
#bladdercancer #HIVEC #CombatCancer
It's #UrologyAwarenessMonth, raising the profile of urological diseases, including bladder cancer. Caught early, bladder cancer survival rates can be as high as 90%. Blood in the urine (haematuria) is the main symptom and should always be checked by a GP.
#HIVEC #CombatCancer
Combat Medical #HIVEC #HIPEC retweeted
This week's goods news from the Leicester Clinical Trials Unit! (2/2) 👇
@ROMATrial_UK @HIVEC_HEAT @coloprevent
Great news @gloshospitals – a third participant recruited to the @HIVEC_HEAT phase 3 trial assessing Combat’s HIVEC® treatment of BCG-unresponsive non-muscle-invasive bladder cancer!
#HIVEC #CombatCancer
CONGRATULATIONS to @gloshospitals for recruiting their 3rd participant.
Keep up the good work team.
@CombatCancer @LeicesterCTU
The Combat PRS+ (Peritoneal Recirculation System +Agitation) optimises HIPEC – hyperthermic intraperitoneal chemotherapy – to improve drug penetration into peritoneal tumours, including colorectal, ovarian and pancreatic cancer.
#HIPEC #CombatCancer
The Combat BRS is our HIVEC® drug-delivery treatment with mitomycin C for NMIBC, currently being evaluated in the @HIVEC_HEAT phase 3 trial. It uses clinical hyperthermia to substantially increase chemotherapy effectiveness vs room-temperature instillation.
#HIVEC #CombatCancer
Delighted to report the recruitment of our 11th patient into the phase 3 @HIVEC_HEAT trial for Combat’s HIVEC® treatment of BCG-unresponsive non-muscle-invasive bladder cancer!
#HIVEC #CombatCancer
As use of GLP-1s becomes increasingly widespread, what do we really know about their relationship with #PancreaticCancer? A new review finds that current clinical evidence is reassuring, but longer-term studies remain essential.
👉bit.ly/4pZHvMH
#HIPEC #CombatCancer
Delighted that @imperial_n86543 has recruited its first @HIVEC_HEAT patient for our phase 3 trial investigating the efficacy & safety of the Combat BRS #HIVEC® treatment with mitomycin C for NMIBC as a bladder-sparing alternative in BCG-unresponsive patients.
#CombatCancer
Congratulations to Imperial College Healthcare NHS Trust for recruiting their first #HIVECHEAT participant.
Amazing and thank you for your hard work.
@LeicesterCTU @trlgriffiths @CombatCancer
Supported with a @bowelcanceruk grant, researchers at @ICR_London and St Mark’s Hospital London are developing a non-invasive way to predict bowel cancer risk in people with IBD, who have a higher risk of developing bowel cancer.
👉bit.ly/4pypSDn
#HIPEC #CombatCancer
Delighted to announce the recruitment of another participant to the @HIVEC_HEAT phase 3 trial for patients with BCG-unresponsive NMIBC.
#HIVEC #HIVECHEAT #CombatCancer
A study of >96k colorectal cancer cases has found incidence in Swiss adults aged <50yrs rose 0.5% per year between 1980-2021, with more younger patients presenting with metastatic disease than older patients.
▶️bit.ly/4aJ7RfJ
#HIPEC #CombatCancer
Combat Medical #HIVEC #HIPEC retweeted
🌍 New report from @WHO: Global Status Report on Cancer 2026
📘 A first-ever survey across 116 countries shows what cancer really does to a life: lost income, strained relationships, chronic pain, isolation.
For #BladderCancer, that includes continence changes, stigma, and feeling excluded from treatment decisions.
👉 Learn more: who.int/news/item/08-07-2026…
#Cancer is not just a disease.
It is a family story, a caregiving story, a community story.
Many of us may navigate it - after receiving the diagnosis or as a friend or family member providing care and support.
It can be tough. But there is hope.
Stronger prevention, better earlier detection, quality treatment and palliative care, when available to everyone — can change the outcome of your cancer journey bit.ly/4wxY9VT
Great to read the latest updates for the @HIVEC_HEAT trial!
#medicalinnovation #HIVEC #bladdercancer #CombatCancer
Happy Tuesday and rounding off the month, hot off the virtual presses, here is Junes Newsletter.
Stay cool, stay hydrated and stay informed on all things HIVEC-HEAT.
#HIVEC #HIVECHEAT #LEICESTERCTU @CombatCancer @LeicesterCTU
5 NHS hospitals have started diagnosing bladder cancer using a home-based urine test that's more accurate, faster and more acceptable for patients than cystoscopy: 92.2% overall sensitivity & 92% specificity vs 81% and 73% with cystoscopy.
#medicalinnovation #HIVEC #CombatCancer
It’s Cancer Prevention Action Week – did you know that 4 in 10 cancer cases in the UK are preventable? That's 54% of bowel cancer, 49% of bladder cancer, 37% of pancreatic cancer and 11% of ovarian cancer.
#CancerPreventionActionWeek #ScienceNotFiction #HIVEC #HIPEC #CombatCancer








